Gilead Sciences | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
AbbVie USD 3.86B 306M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Eli Lilly USD 2.42B 324.7M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
Glaxosmithkline GBP 2.7B 632M 2024-12
Incyte USD 326.71M 17.5M 2024-12
J&J USD 5.11B 1.34B 2025-03
Merck USD 2.53B 319M 2025-03
Moderna USD 351M 70M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
PTC Therapeutics USD 84.68M 11.23M 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Sanofi EUR 2.68B 26M 2024-09
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
United Therapeutics USD 162.5M 8.4M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Gilead Sciences Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.